https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-09-21 / Mol. Cancer Ther. 2010 Oct;9(10):2761-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-09-21 / Mol. Cancer Ther. 2010 Oct;9(10):2761-92010-09-21 00:00:002010-09-21 00:00:00Genetically engineered oncolytic Newcastle disease virus effectively induces sustained remission of malignant pleural mesothelioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-06-01 / Expert Rev Respir Med 2010 Jun;4(3):311-4
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-06-01 / Expert Rev Respir Med 2010 Jun;4(3):311-42010-06-01 00:00:002010-06-01 00:00:00Dendritic cell vaccination as a treatment modality for mesothelioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-02-18 / Am. J. Respir. Crit. Care Med. 2010 Jun;181(12):1383-90
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-02-18 / Am. J. Respir. Crit. Care Med. 2010 Jun;181(12):1383-902010-02-18 00:00:002020-09-07 08:01:07Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-01-30 / Cell Adh Migr 2010 Jan-Mar;4(1):153-61
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-01-30 / Cell Adh Migr 2010 Jan-Mar;4(1):153-612010-01-30 00:00:002019-02-15 08:50:36What’s the place of immunotherapy in malignant mesothelioma treatments?
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-08-01 / Int J Hyperthermia 2007 Aug;23(5):431-42
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-08-01 / Int J Hyperthermia 2007 Aug;23(5):431-422007-08-01 00:00:002007-08-01 00:00:00Laboratory and clinical basis for hyperthermia as a component of intracavitary chemotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-02-01 / Cir Esp 2007 Feb;81(2):82-6
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-02-01 / Cir Esp 2007 Feb;81(2):82-62007-02-01 00:00:002007-02-01 00:00:00[Malignant peritoneal mesothelioma. Our experienced with triple combined therapy: cytoreduction, intraperitoneal perioperative chemotherapy and hyperthermia]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-01-01 / Bull Cancer 2007 Jan;94(1):23-31
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-01-01 / Bull Cancer 2007 Jan;94(1):23-312007-01-01 00:00:002007-01-01 00:00:00[Immunotherapy and malignant mesothelioma: clinical perspectives]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-11-01 / Int J Hyperthermia 2006 Nov;22(7):613-21
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-11-01 / Int J Hyperthermia 2006 Nov;22(7):613-212006-11-01 00:00:002006-11-01 00:00:00Hyperthermia combined with intra-thoracic chemotherapy and radiotherapy for malignant pleural mesothelioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-03-15 / Eur. Respir. J. 2006 Jun;27(6):1086-95
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-03-15 / Eur. Respir. J. 2006 Jun;27(6):1086-952006-03-15 00:00:002006-03-15 00:00:00Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-03-11 / Am. J. Respir. Crit. Care Med. 2005 May;171(10):1168-77
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-03-11 / Am. J. Respir. Crit. Care Med. 2005 May;171(10):1168-772005-03-11 00:00:002019-02-15 08:50:35Immunotherapy of murine malignant mesothelioma using tumor lysate-pulsed dendritic cells
